Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadekinig alfa in Adult-Onset Still's Disease
NCT02398435Phase 2Completed
- Sponsor
- AB2 Bio Ltd.
- Start
- Feb 2015
- Primary completion
- Jun 2016
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of tadekinig alfa in adult-onset Still's disease (AOSD), sponsored by AB2 Bio Ltd.. Started Feb 2015; status: completed.
02
Drugs
tadekinig alfa
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on NCT02398435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02398435.